Roche looking to expand oncology

At their recent investor conference Roche announced that they plan to increase their presence in oncology. They're currently the leading player in the oncology sector, as 53% of their 2009 sales came from that sector. Their current pipeline for oncology includes: several new drugs such as pertuzumab and T–DM1 for HER2-positive breast cancer, RG7204 for the treatment of malignant melanoma, GA101/RG7159 for chronic lymphocytic leukemia and non-Hodgkin’s lymphoma, and RG3616 for the treatment of advanced basal cell carcinoma and potentially other cancers such as colorectal cancer.

Read the full article here.

This post is brought to you by:


Target Clinical Trial Series: The Optimal Approaches to Oncology Clinical Trial Design and Analysis brings together colleagues in biostatistics, oncology clinical trials, clinical R&D, adaptive trials, oncology drugs and diagnostics, and translational research in an exciting and engaging environment to deliver and develop solutions, industry standards and practical applications for clinical trial design and analysis.

This event, along with the entire Target Clinical Trials Series is FREE to clinical research professionals from a pharmaceutical or biotech company.

Share this article with your social network, just click below to share now!

Share |